{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:17:01Z","timestamp":1790849821336,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.crd.0000148236.34855.18","type":"journal-article","created":{"date-parts":[[2005,10,17]],"date-time":"2005-10-17T05:48:20Z","timestamp":1129528100000},"page":"297-303","source":"Crossref","is-referenced-by-count":11,"title":["Angiotensin Receptor Blockers in Congestive Heart Failure"],"prefix":"10.1097","volume":"13","author":[{"given":"Vishal","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boban","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin\u2013angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.","volume":"49","author":"Levine","year":"1982","journal-title":"Am J Cardiol"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/clc.4960190602","article-title":"Wound healing following myocardial infarction.","volume":"19","author":"Weber","year":"1996","journal-title":"Clin Cardiol"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1067\/mhj.2000.109215","article-title":"Rationale for the use of combination angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker therapy in heart failure.","volume":"140","author":"Carson","year":"2000","journal-title":"Am Heart J"},{"issue":"suppl","key":"R4-5-20210203","first-page":"VI40","article-title":"Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9149(99)80748-6","article-title":"Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators.","volume":"75","author":"Benedict","year":"1995","journal-title":"Am J Cardiol"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0735-1097(99)00025-X","article-title":"Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.","volume":"33","author":"Brunner-La Rocca","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u2018Escape\u2019 of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.","volume":"73","author":"Lee","year":"1986","journal-title":"Circulation"},{"issue":"suppl N","key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","article-title":"Aldosterone escape during ACE inhibitor therapy in chronic heart failure.","volume":"16","author":"Struthers","year":"1995","journal-title":"Eur Heart J"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.","volume":"99","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1161\/01.CIR.100.22.2224","article-title":"Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.","volume":"100","author":"Riegger","year":"1999","journal-title":"Circulation"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","article-title":"Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.","volume":"139","author":"Granger","year":"2000","journal-title":"Am Heart J"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.91.3.691","article-title":"Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.","volume":"91","author":"Crozier","year":"1995","journal-title":"Circulation"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0735-1097(98)00695-0","article-title":"Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.","volume":"33","author":"Havranek","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0167-5273(98)00149-1","article-title":"Valsartan in heart failure patients previously untreated with an ACE inhibitor.","volume":"65","author":"Mazayev","year":"1998","journal-title":"Int J Cardiol"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0735-1097(97)00253-2","article-title":"Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.","volume":"30","author":"Lang","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0735-1097(95)80020-H","article-title":"Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.","volume":"26","author":"Dickstein","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II.","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/01.CIR.91.7.2043","article-title":"Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.","volume":"91","author":"McDonald","year":"1995","journal-title":"Circulation"},{"key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.CIR.99.8.990","article-title":"Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure.","volume":"99","author":"Hamroff","year":"1999","journal-title":"Circulation"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1742-1241.2000.tb11833.x","article-title":"A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.","volume":"54","author":"Tonkon","year":"2000","journal-title":"Int J Clin Pract"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1067\/mhj.2001.114802","article-title":"ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.","volume":"141","author":"Murdoch","year":"2001","journal-title":"Am Heart J"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/01.CIR.0000091234.45664.62","article-title":"Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.","volume":"108","author":"Cohn","year":"2003","journal-title":"Circulation"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(99)80027-0","article-title":"HOPE for cardiovascular disease prevention with ACE inhibitor ramipril. Heart Outcomes Prevention Evaluation.","volume":"354","author":"Kleinert","year":"1999","journal-title":"Lancet"},{"key":"R39-5-20210203","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"R40-5-20210203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R41-5-20210203","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II).","volume":"27","author":"Swedberg","year":"1992","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.crd.0000148236.34855.18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:57:30Z","timestamp":1785855450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-200511000-00005"}},"subtitle":["Evidence, Concerns, and Controversies"],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000148236.34855.18","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}